United States Patent 9,987,238 (Acetaminophen IV): Claim Scope, Patent-Types Covered, and US Landscape
US Patent 9,987,238 is centered on a pain-treatment method in humans using an intravenous (IV) acetaminophen regimen that delivers ~500 mg to ~750 mg per dose with re-dosing at least every 4 hours, where the analgesic effect is comparable to oral 1000 mg every 6 hours. Dependent claims narrow the regimen by daily dose ceiling (<4 g/24h), dosing frequency (≥6 times/24h), and multiple formulation parameters (dose band, antioxidant inclusion, buffering agent species, pH, osmolarity/isotonicity agents, lyophilized form, reconstitution, infusion time window).
Because the claims are drafted as a method-of-treatment claim set with formulation and administration constraints, infringement is driven by (i) the exact IV dose range and interval, (ii) whether the product can be characterized to fall within the pH/osmolarity/isotonicity/buffering and antioxidant dependent claim limitations, and (iii) performance characterization using the “comparable to” oral standard-of-care language.
What is the scope of US Patent 9,987,238 claims for IV acetaminophen pain treatment?
Core independent claim 1 scope (method + regimen + IV dosing + performance comparator).
Claim 1 requires all elements:
- Indication: “method of treating pain in a human subject” needing treatment.
- Population: subject weighing at least 50 kg.
- Drug and dose per administration: IV pharmaceutical composition containing about 500 mg to about 750 mg acetaminophen.
- Re-dosing interval: “repeating … at least once every four hours.” (So interval ≤4 hours; i.e., more frequent than or equal to q4h.)
- Route: intravenous administration.
- Performance/translation constraint: “therapeutic effect … comparable to standard of care treatment of 1000 mg acetaminophen orally every 6 hours.”
Practical read-through.
Claim 1 is not limited to a particular salt/form of acetaminophen or a specific vehicle in the independent claim. It is, however, locked to a narrow IV per-dose band (500–750 mg), a re-dosing cadence (≤4h), and an outcome equivalency framing against an oral comparator regimen.
How broad is the dose and interval coverage?
- Dose: “about 500 mg to about 750 mg.” “About” typically creates room for minor deviation, but the claim is still anchored to that 250 mg span.
- Interval: “at least once every four hours” translates to administer at least every 4 hours. A generic label with q6h would not satisfy this interval; a regimen with q4h or more frequent would be at/within scope.
What does “comparable to” oral 1000 mg q6h mean for infringement?
- It is a functional performance limitation. In litigation, it tends to drive expert testimony and clinical bridging arguments (e.g., analgesic endpoints, time to meaningful pain reduction, or equivalent pain intensity difference) and can be attacked as indefinite or litigated as a factual question.
- The claim ties IV use to an accepted oral regimen benchmark: 1000 mg oral q6h.
Which dependent claims in US 9,987,238 narrow dosing frequency, total daily dose, and specific dose amounts?
Daily ceiling and dosing frequency
- Claim 2: method of claim 1 where subject is administered less than 4 grams acetaminophen over 24 hours.
- This constrains the total daily exposure even if the per-dose band and interval otherwise fit claim 1.
- Claim 3: method of claim 1 where the composition is administered at least six times in 24 hours.
- Six doses/24h implies an average spacing of about ≤4 hours (consistent with claim 1’s q4h minimum frequency). Practically, it overlaps with q4h schedules (6 doses in 24h is consistent with q4h if dosing begins at time 0 and last at time 20h, or with adjustments).
Dose band narrowing
- Claim 4: composition has about 600 mg to about 700 mg acetaminophen.
- Claim 5: composition has about 650 mg acetaminophen.
These narrow the potential design-around space: a product sitting at ~500 mg or ~750 mg is within claim 1 but may fall outside claims 4 and 5.
What formulation features are claimed in US 9,987,238 beyond dose and route?
Even though independent claim 1 does not require a specific formulation package, dependent claims incorporate multiple product-characterizing variables that can support both infringement and validity arguments in a challenge.
Antioxidant requirement
- Claim 6: composition further comprises at least one antioxidant.
- Claim 7: antioxidant is cysteine hydrochloride monohydrate.
This is a significant narrowing limitation. A generic IV acetaminophen solution without this antioxidant system may avoid claims 6–7 while still reading on claim 1 if other elements are met.
Buffering agent selection
- Claim 8: further comprises a buffering agent.
- Claim 9: buffering agent is selected from a list of pharmaceutically acceptable salts/acids including:
- citrate, phosphate, acetate, glutamate, tartate, benzoate, lactate, histidine or other amino acids, gluconate, malate, succinate, formate, proprionate, carbonate, and combinations.
- Claim 10: buffering agent is disodium phosphate dehydrate.
This creates a potential “fork” for design-around: a product using a non-enumerated buffer or different buffer form may fall outside dependent claims 9–10.
pH and osmolarity windows
- Claim 11: pH 4 to 8.
- Claim 12: pH 5 to 6.
- Claim 13: osmolarity 200 to 400 mOsm/L.
These are typical formulation parameters for injectable stability and tolerability. Claim 12’s 5–6 band is a meaningful narrowing versus the wider 4–8.
Isotonicity agent
- Claim 14: further comprises an isotonicity agent.
- Claim 15: isotonicity agent selected from dextrose, mannitol, lactose.
- Claim 16: isotonicity agent is mannitol.
Solid dosage form and reconstitution
- Claim 17: composition is a lyophilized powder.
- Claim 18: lyophilized powder is reconstituted in solution prior to administration.
Infusion duration limitation
- Claim 19: IV administered over about 5 to about 30 minutes.
- Claim 20: IV administered over about 15 minutes.
This can be a key infringement lever: IV acetaminophen products are often administered over a defined infusion time. A different infusion duration could potentially avoid claims 19–20 while remaining within claim 1 if claim 1’s independent elements are otherwise met.
How does the claim structure affect infringement risk for generic/authorized IV acetaminophen?
Highest-risk infringement path is claim 1, because it is the broadest: it requires pain treatment, adult weight ≥50 kg, IV dosing of ~500–750 mg per administration, q4h-or-more-frequent redosing, and analgesic comparability to oral 1000 mg q6h.
Lower-risk but still meaningful exposure exists for dependent claims when a competitor product matches specific formulation and administration features:
- Antioxidant system: cysteine hydrochloride monohydrate
- Buffer system: disodium phosphate dehydrate (or other buffers listed)
- pH: 5–6 band
- Osmolarity: 200–400 mOsm/L
- Isotonicity: mannitol
- Dosage form: lyophilized powder and reconstitution
- Infusion time: ~15 minutes
Design-around strategy implied by claim dependencies:
A competitor can reduce literal infringement odds by departing from one or more of the dependent limitations (e.g., change antioxidant system, buffer species, pH band, infusion time), but it cannot avoid claim 1 unless it also changes one of the independent essentials, especially:
- the dose range (500–750 mg),
- the redosing interval (≤4 hours),
- the IV route, or
- the “comparable” analgesic performance condition.
What patent “types” does US 9,987,238 cover: method-of-use vs formulation vs admin schedule?
This patent is best understood as a method-of-use claim set that embeds product and process descriptors:
- Method-of-treatment: explicit “treating pain” in a human subject.
- Regimen claim elements: dose per administration, dosing interval, daily dose cap, dosing frequency.
- Formulation-characterizing dependent claims: antioxidant, buffer identity, pH, osmolarity, isotonicity agent.
- Administration technique characterization: infusion time, lyophilized formulation and reconstitution.
That combination matters because it can reach parties beyond simple product manufacture:
- prescribing physicians and facilities,
- distributors providing the labeled regimen,
- and possibly sponsors who market and instruct the regimen to match the claim-limited parameters.
What does the “comparable to oral 1000 mg q6h” limitation mean for regulatory labeling strategy?
For a product to be positioned to satisfy claim 1, it must be used in a way that supports a clinical equivalence narrative to oral 1000 mg q6h. In practice, that pushes the FDA-facing labeling strategy toward:
- analgesic effectiveness characterization against a benchmark regimen,
- and label alignment with dose interval used in the claim (q4h or more frequent).
A competitor seeking to avoid claim 1 would look to:
- label dosing at intervals longer than q4h (e.g., q6h),
- or structure regimens outside the 500–750 mg per-dose band,
- or avoid the analgesic equivalence framing.
How many claim limitations create potential invalidity or noninfringement targets?
This claim set has a layered limitation profile that supports multiple attack vectors:
Noninfringement targets
- Dose per administration outside ~500–750 mg
- Dosing interval longer than 4 hours
- Oral comparison mismatch in practice (harder, because performance is baked into claim 1)
- Lack of antioxidant (for dependent claims 6–7)
- Buffer not matching dependent claim species (claims 9–10)
- pH outside 5–6 (claim 12) or osmolarity outside 200–400 (claim 13)
- Different isotonicity agent (for claims 15–16)
- Not lyophilized or different reconstitution scheme (claims 17–18)
- Different infusion time (claims 19–20)
Validity targets
The dense feature set (dose band, interval, “comparable” outcome, and formulation specs) is often where prior art can be mapped, but the specific strength cannot be assessed without the patent specification and cited references, which are not provided here.
What is the likely competitive landscape for IV acetaminophen methods matching this claim?
At a high level, IV acetaminophen competitors and authorized generics in the US market are likely to cluster around:
- single-dose strengths in the mid-hundreds of mg,
- dosing intervals aligned to analgesic effect,
- infusion times (often ~15 minutes),
- and formulation systems for stability including buffers and isotonicity.
This patent’s dependent claim feature choices (cysteine hydrochloride monohydrate, disodium phosphate dehydrate, mannitol, lyophilized powder, pH 5–6, osmolarity 200–400 mOsm/L) indicate it is aimed at a specific marketed formulation and administration protocol, not just any IV acetaminophen.
The highest infringement risk tends to fall on products whose labels and manufacturing match these exact parameter choices, especially for claim 12, 13, 16, 19, and 20.
Key takeaways
- US 9,987,238 is a method-of-treatment patent with embedded regimen and formulation constraints for IV acetaminophen in pain treatment.
- Claim 1 is the principal risk anchor: ~500–750 mg IV, q4h-or-more-frequent, human weight ≥50 kg, and analgesic effect comparable to oral 1000 mg q6h.
- Dependent claims narrow exposure by adding daily ceiling (<4 g/24h), ≥6 doses/24h, dose band 600–700 mg (or ~650 mg), and specific formulation features including cysteine hydrochloride monohydrate, disodium phosphate dehydrate, pH 5–6, osmolarity 200–400 mOsm/L, mannitol, and ~15-minute infusion plus lyophilized/reconstituted administration.
FAQs
1) What single claim element most easily supports a noninfringement argument?
Dosing interval: a regimen that is not at least once every four hours can avoid claim 1.
2) If a product uses the same IV dose but different infusion time, does it avoid infringement?
It may avoid dependent claims 19–20, but it does not automatically avoid claim 1 unless the infusion change also affects the claim 1-required elements.
3) Can a manufacturer avoid dependent claims by changing the antioxidant?
Yes for dependent claims 6–7, which specifically require an antioxidant and, in claim 7, cysteine hydrochloride monohydrate.
4) How do buffering agent choices affect claim coverage?
Dependent claim 9 lists acceptable buffers and claim 10 locks to disodium phosphate dehydrate; changing buffer outside those parameters can avoid claims 9–10.
5) Does “about” in the dose range materially widen infringement exposure?
It widens the literal range slightly, but claim scope remains anchored to 500–750 mg and dependent claims further narrow to 600–700 mg and ~650 mg.
References
(No sources cited because the full patent bibliographic record, specification, prosecution history, and prosecution-cited prior art were not provided in the input.)
